It has been reported that CDK4 knockdown impedes the colony formation and cell proliferation of glioma [36], and that PBK and SLC2A3 could be a potential prognostic factor and therapeutic target for GBM treatment [37,38]. The gene discussed is CDK4; the disease is glioblastoma.